Iza-Bren(EGFR-HER3双抗ADC)治疗广泛期小细胞肺癌的Ib期研究结果
这项开放标签、多中心、剂量扩展Ib期研究评估了首创新药EGFR-HER3双特异性抗体偶联药物iza-bren在经治广泛期小细胞肺癌(ES-SCLC)中的疗效与安全性,52例患者接受2.5 mg/kg(每3周周期第1、8天)治疗,总ORR为48.1%,二线亚组ORR达72.7%,常见不良事件为血液学毒性,探索性分析提示HER3阳性可能与更好疗效相关。
要点
- 经治ES-SCLC总体ORR 48.1%,二线亚组ORR 72.7%。
- 总体中位PFS 4.1个月,中位OS 12.2个月。
- 最常见治疗相关不良事件为血液学毒性。
核心结论
- Iza-bren在复发ES-SCLC中显示出令人鼓舞的抗肿瘤活性,尤其在二线治疗中。
- 一项比较iza-bren与拓扑替康的III期随机对照试验正在进行中。
研究设计与样本
- 开放标签、多中心、剂量扩展Ib期研究(NCT05194982)。
- 纳入既往系统治疗后进展的ES-SCLC患者,共52例。
- 给药方案为iza-bren 2.5 mg/kg,每3周周期第1天和第8天每日一次。
- 主要终点为客观缓解率(ORR)和安全性/耐受性。
主要发现
- 总体ORR为48.1%(95% CI 34.0-62.4)。
- 总体中位PFS为4.1个月(95% CI 3.0-5.5),中位OS为12.2个月(95% CI 9.1-13.2)。
- 二线治疗亚组(n=22)ORR为72.7%(95% CI 49.8-89.3),中位PFS 6.2个月(95% CI 3.7-8.2),中位OS 15.0个月(95% CI 8.7-未达到)。
- 最常见治疗相关不良事件为血液学毒性(中性粒细胞减少、血小板减少、贫血和白细胞减少)。
- 探索性生物标志物分析提示HER3阳性表达可能与更好的治疗反应相关。
临床怎么用
- 对于经治ES-SCLC患者,iza-bren可作为潜在治疗选择,尤其二线治疗显示较高缓解率。
- 治疗期间需密切监测血液学毒性。
局限性
- 本研究为单臂Ib期剂量扩展研究,样本量有限,结论需III期随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, with limited treatment options beyond frontline chemo-immunotherapy. Izalontamab brengitecan (iza-bren, BL-B01D1) is a first-in-class bispecific antibody-drug conjugate cotargeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). We expanded the SCLC cohort to further evaluate the efficacy and safety of iza-bren in patients with extensive-stage SCLC (ES-SCLC). METHODS: This open-label, multicenter, dose-expansion phase Ib study (ClinicalTrials.gov identifier: NCT05194982) enrolled patients with ES-SCLC who had progressed on prior systemic therapies. Patients received iza-bren 2.5 mg/kg once daily on days 1 and 8 of each 3-week cycle. The primary end points were objective response rate (ORR) and safety/tolerability. Secondary end points included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory end point included the assessment of potential associations between EGFR/HER3 expression and clinical outcomes. RESULTS: As of December 5, 2024, 52 patients were enrolled. The ORR was 48.1% (95% CI, 34.0 to 62.4), with a median PFS of 4.1 months (95% CI, 3.0 to 5.5) and a median OS of 12.2 months (95% CI, 9.1 to 13.2). In patients who received iza-bren as second-line treatment (n = 22), the ORR was 72.7% (95% CI, 49.8 to 89.3), median PFS 6.2 months (95% CI, 3.7 to 8.2), and median OS 15.0 months (95% CI, 8.7 to not reached). The most common treatment-related adverse events were hematologic toxicities (neutropenia, thrombocytopenia, anemia, and leukopenia). Exploratory biomarker analysis suggested that positive HER3 expression may be associated with better treatment response. CONCLUSION: Iza-bren showed encouraging antitumor activity in relapsed ES-SCLC, particularly in the second-line setting. A phase III randomized controlled trial of iza-bren compared with topotecan (ClinicalTrials.gov identifier: NCT06500026) is ongoing.
引用
- Zhao Y, Zhao H, Wang Q, et al. Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. J Clin Oncol. 2026. PMID: 42497381. doi:10.1200/JCO-26-00243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。